autoimmune

Boehringer Ingelheim Leverages IBM’s AI Tech for Novel Antibody Development

(IN BRIEF) Boehringer Ingelheim and IBM have formed a partnership to expedite the discovery of novel candidate antibodies for therapeutic…

5 months ago

SAVOR-TIMI-53 cardiovascular outcomes trial of ONGLYZA® results announced by AstraZeneca and Bristol-Myers Squibb

20-6-2013 — /europawire.eu/ — AstraZeneca and Bristol-Myers Squibb announced today top-line results of the Phase IV SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular…

11 years ago